Author information
1Fellow, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA USA.
2Resident, Department of Medicine, Emory University School of Medicine, Atlanta, GA USA.
3Assistant Professor of Medicine, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Staff Physician, Atlanta VA Medical Center, Atlanta, GA USA.
4Assistant Professor, Division of Digestive Diseases and Emory Transplant Center, Department of Medicine, Emory University School of Medicine, Atlanta, GA USA.
5Professor of Medicine and Digestive Diseases, Director, Division of Digestive Diseases, Emory University School of Medicine, Staff Physician, Atlanta VA Medical Center, Atlanta, GA USA.
6Professor of Medicine and Infectious Diseases, Director, Division of Infectious Diseases, Emory University School of Medicine, Staff Physician, Atlanta VA Medical Center, Atlanta, GA USA.
Abstract
Treatment of HCV with potent, interferon-free, direct acting antiviral regimens with no activity against HBV may increase the risk for HBV reactivation in co-infected patients. We present two cases of HBV reactivation during treatment with an all oral regimen of simeprevir and sofosbuvir and discuss strategies to prevent HBV flare.